Peripheral Vascular Disease (PVD) News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.AHA Urges Greater Attention to Peripheral Artery Disease AHA Urges Greater Attention to Peripheral Artery Disease
Despite its prevalence and clinical importance, PAD has been underappreciated, under-recognized and undertreated, the AHA says in a new scientific statement.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 13, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Growing vascular treatment group expands to Overland Park
A medical group that focuses on preventing unnecessary amputations is expanding to Overland Park.
Modern Vascular is opening a clinic at 5320 College Blvd. It is the Phoenix-based group’s 16th location and its first in the Kansas City area. Dr. Juan Carlos Correa is the managing physician for the Overland Park clinic, according to a release.
The clinic will specialize in outpatient treatmen t of peripheral artery disease. The condition, caused by fatty deposits in artery walls, reduces blood flow… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 9, 2021 Category: Pharmaceuticals Authors: Brian Kaberline Source Type: news
Growing vascular treatment group expands to Overland Park
A medical group that focuses on preventing unnecessary amputations is expanding to Overland Park.
Modern Vascular is opening a clinic at 5320 College Blvd. It is the Phoenix-based group’s 16th location and its first in the Kansas City area. Dr. Juan Carlos Correa is the managing physician for the Overland Park clinic, according to a release.
The clinic will specialize in outpatient treatmen t of peripheral artery disease. The condition, caused by fatty deposits in artery walls, reduces blood flow… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 9, 2021 Category: Biotechnology Authors: Brian Kaberline Source Type: news
Modern Vascular enters St. Louis market with new clinic
A Phoenix-based medical group that specializes in the treatment of peripheral artery disease is adding its 15th clinic nationwide in the St. Louis area. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 4, 2021 Category: Health Management Authors: Diana Barr Source Type: news
Modern Vascular Announces Hiring of Dr. Steve Berkowitz
Company's first full-time Chief Medical Officer is a renowned expert in process improvement, healthcare reform, and ensuring superior clinical outcomes
PHOENIX, June 28, 2021 -- (Healthcare Sales & Marketing Network) -- Modern Vascular, a pioneering me... Devices, Interventional, Personnel Modern Vascular, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2021 Category: Pharmaceuticals Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cagent Vascular receives $9M investment to accelerate marketing of its lead product
The FDA granted marketing clearance last year for the company's product used to treat below-the-knee peripheral artery disease. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 21, 2021 Category: Pharmaceuticals Authors: John George Source Type: news
Cagent Vascular receives $9M investment to accelerate marketing of its lead product
The FDA granted marketing clearance last year for the company's product used to treat below-the-knee peripheral artery disease. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 21, 2021 Category: Biotechnology Authors: John George Source Type: news
Blood Lipid Control Inadequate in PAD Patients Blood Lipid Control Inadequate in PAD Patients
Lipid-lowering therapy remains underused and LDL-C is poorly controlled in many patients with peripheral artery disease, a new study shows.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 18, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
High'Remnant' Cholesterol Linked to Fivefold Increase in PAD High'Remnant' Cholesterol Linked to Fivefold Increase in PAD
High levels of remnant cholesterol were associated with an increased risk for peripheral artery disease of up to fivefold in a large Danish analysis, although questions remain over its current clinical utility.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 2, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery Disease
Title: Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery DiseaseCategory: Health NewsCreated: 4/9/2021 12:00:00 AMLast Editorial Review: 4/12/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 12, 2021 Category: Cardiology Source Type: news
AHA News: Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery Disease
FRIDAY, April 9, 2021 (American Heart Association News) -- Abigail Dudek celebrated her 40th birthday in Las Vegas a few months ago, grateful to go hiking and cycling without pain for the first time in more than two years.
The problem started in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2021 Category: General Medicine Source Type: news
For People With PAD, Exercise Can Be Tough But Rewarding
WEDNESDAY, April 7, 2021 -- Fast-paced walking is painful for the millions of people with peripheral artery disease (PAD). But new research shows that a slower, pain-free pace won ' t cut it if improvement in mobility is the goal.
The study included... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 7, 2021 Category: General Medicine Source Type: news
No pain, no gain in exercise for peripheral artery disease
(Northwestern University) No pain means no gain when it comes to reaping exercise benefits for people with peripheral artery disease, reports a new study. In people with peripheral artery disease, walking for exercise at an intensity that induces ischemic leg pain (caused by restricted blood flow) improves walking performance -- distance and length of time walking -- the study found. Walking at a slow pace that does not induce ischemic leg symptoms is no more effective than no exercise at all, the study showed. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 6, 2021 Category: International Medicine & Public Health Source Type: news
